---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-060001"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:42:31.696750+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reports FY2023 revenue $113.3M; cash runway into Q4 2025; INHBE candidate selected

## Summary
- Cash and equivalents $200.4M at Dec 31, 2023; additional $34M received in Q1 2024; runway expected into Q4 2025.
- Full-year revenue $113.3M (2022: $3.6M) driven by GSK and Takeda collaborations; net loss improved to $57.5M from $161.8M.
- INHBE lead clinical candidate for obesity selected; GalNAc-siRNA shows potent silencing, weight loss without muscle loss; trial initiation expected Q1 2025.
- Proof-of-mechanism data for WVE-006 in AATD expected 2024; WVE-N531 dystrophin data in DMD expected Q3 2024; WVE-003 multi-dose HD data expected Q2 2024.

## SEC filing metadata
- accession: 0001193125-24-060001
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524060001/0001193125-24-060001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524060001/d761944d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-060001
- JSON: https://secwatch.observer/filing/0001193125-24-060001.json
- Plain text: https://secwatch.observer/filing/0001193125-24-060001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.